The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6)

Drug Metabolism and Disposition

Volumn 25, Issue 5, 1997, Pages 651-655

  Rodrigues, A David ^a   Roberts, Ellen M ^b  

^a MERCK RESEARCH LABORATORIES   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 ISOENZYME; DEXMEDETOMIDINE; DEXTROMETHORPHAN; O DEMETHYLASE; QUINIDINE;

ARTICLE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; ENZYME ACTIVITY; HUMAN; HUMAN TISSUE; KINETICS; LIVER METABOLISM; LIVER MICROSOME; PRIORITY JOURNAL; SPECTROSCOPY;

CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME INHIBITORS; HUMANS; IMIDAZOLES; MEDETOMIDINE; MICROSOMES, LIVER; OXIDOREDUCTASES, O-DEMETHYLATING; QUINIDINE; RECOMBINANT PROTEINS; TUMOR CELLS, CULTURED;

EID: 0030996094     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. 2-adrenergic agonists during general anaesthesia. Anaesth. Pharmacol. Rev. 1, 268-283 (1993).
2. 2-adrenergic agonists and perioperative ischaemia. Anaesth. Pharmacol. Rev. 1, 10-15 (1993).
3. 2-adrenergic agonists: strategies for the rational use of these novel anesthetic agents. J. Clin. Anesthesiol. 1, 146-157 (1988).
4. J. P. Belleville, D. S. Ward, B. C. Bloor, and M. Maze: Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation and metabolic rate. Anesthesiology 77, 1125-1133 (1992).
5. M. Murray and C. F. Wilkinson: Interactions of nitrogen heterocycles with cytochrome P450 and monooxygenase activity. Chem.-Biol. Interact. 50, 267-275 (1984).
6. P. J. Little and A. J. Ryan: Inhibitors of hepatic mixed-function oxidases. 4. Effects of benzimidazoles and related compounds on aryl hydrocarbon hydroxylase activity from phenobarbitone and 3-methylcholanthrene induced rats. J. Med. Chem. 25, 622-626 (1982).
7. T. D. Rogerson, C. F. Wilkinson, and K. Hetarski: Steric factors in the inhibitory interaction of imidazoles with microsomal enzymes. Biochem. Pharmacol. 26, 1039-1042 (1977).
8. B. Testa and P. Jenner: Inhibitors of cytochrome P450s and their mechanism of action. Drug Metab. Rev. 12, 1-117 (1981).
9. O. Pelkonen, J. Puurunen, P. Arvela, and R. Lammintausta: Comparative effects of medetomidine enantiomers on in vitro and in vivo microsomal drug metabolism. Pharmacol. Toxicol. 69, 189-194 (1991).
10. E. D. Kharasch, H. F. Hill, and A. C. Eddy: Influence of dexmedetomidine and clonidine on human liver microsomal alfentanil metabolism. Anesthesiology 75, 520-524 (1991).
11. E. D. Kharasch, S. Herrmann, and R. Labroo: Ketamine as a probe for medetomidine stereoisomer inhibition of human liver microsomal drug metabolism. Anesthesiology 77, 1208-1214 (1992).
12. R. B. Labroo, K. E. Thummel, K. L. Kunze, T. Podoll, W. F. Trager, and E. D. Kharasch: Catalytic role of cytochrome P4503A4 in multiple pathways of alfentanil metabolism. Drug Metab. Dispos. 23, 490-496 (1995).
13. T. B. Vree and C. P. W. G. M. Verwey-Van Wissen: Pharmacokinetics and metabolism of codeine in humans. Biopharmaceut. Drug Dispos. 13, 445-460 (1992).
14. O. Mortimer, K. Persson, M. G. Ladona, D. Spalding, U. M. Zanger, U. A. Meyer, and A. Rane: Polymorphic formation of morphine from codeine in poor and extensive metabolizers of dextromethorphan: relationship to the presence of immunoidentified cytochrome P450IID1. Clin. Pharmacol. Ther. 47, 27-35 (1990).
15. F. P. Guengerich: Cytochromes P450 of human liver: Classification and activity profiles of the major enzymes. In: "Advance Drug Metabolism in Man" (G. M. Pacifici and G. N. Fraccia, eds.), pp. 181-231. European Commission, Brussels, Belgium, 1995.
16. 14C]dextromethorphan. Anal. Biochem. 219, 309-320 (1994).
17. C. R. Jefcoate: Measurement of substrate and inhibitor binding to microsomal cytochrome P450 by optical-difference spectroscopy. Methods Enzymol. 52, 258-279 (1978).
18. L. E. Vickery: Active site-directed inhibitors of steroid hydroxylase cytochromes P450. Methods Enzymol. 206, 548-558 (1991).
19. A. D. Rodrigues and S. L. Wong: The utility of in vitro metabolism-based drug-drug interaction studies in drug discovery and development: attempting in vitro-in vivo correlations. In "Pharmacogenetics: Bridging the Gap Between Basic Science and Clinical Application" (J. Schlegel, ed.), pp. 6.2.1-6.2.4. International Business Communications, Inc., Biomedical Library Series, Southborough, MA, 1996.
20. I. H. Segel: Rapid equilibrium partial and mixed-type inhibition. In "Enzyme Kinetics Behavior and Analysis of Rapid Equilibrium and Steady State Enzyme System" pp. 161-226. John Wiley & Sons, New York, 1993.
21. A. Cornish-Bowden: A simple graphical method for determining the inhibition constants of mixed, uncompetitive and noncompetitive inhibitors. Biochem. J. 137, 143-144 (1974).
22. E. A. Dawes: Enzyme kinetics. In "Quantitative Problems in Biochemistry", pp. 126-174. Longman Group Ltd., New York, 1980.
23. F. Broly, C. Libersa, M. Lhermitte, P. Bechtel, and B. Dupuis: Effect of quinidine on dextromethorphan O-demethylase activity of microsomal fractions from human liver. Br. J. Clin. Pharmacol. 28, 29-36 (1989).
24. M. Bourne, V. Meunier, Y. Berger, and G. Fabre: Cytochrome P450 isoform inhibitors as tools for the investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 277, 321-332 (1996).
25. J. Schimder, D. J. Greenblatt, L. L. Von Moltke, J. S. Harmatz, and R. I. Shader: Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O-and N-demethylation. Br. J. Clin. Pharmacol. 41, 339-343 (1996).
26. M. S. Ching, C. L. Blake, H. Ghabrial, S. W. Ellis, M. S. Lennard, G. T. Tucker, and R. A. Smallwood: Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine and its metabolites. Biochem. Pharmacol. 50, 833-837 (1995).
27. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui, and F. P. Guengerich: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drug, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. 270, 414-423 (1994).
28. S. W. Ellis, K. Rowland, M. J. Ackland, E. Rekka, A. P. Simula, M. S. Lennard, C. R. Wolf, and G. T. Tucker: Influence of amino acid residue 374 of cytochrome P450 2D6 (CYP2D6) on the regio-and enantio-selective metabolism of metoprolol. Biochem. J. 316, 647-654 (1996).
29. J. C. Gorski, S. D. Hall, D. R. Jones, M. VandenBranden, and S. A. Wrighton: Regioselective biotransformation of midazolam by members of the human cytochrome P450 3A (CYP3A) subfamily. Biochem. Pharmacol. 47, 1643-1653 (1994).
30. 14C-midazolam in humans following oral dosing. Drug Res. 31, 2220-2223 (1981).